Neutralization of IL-17 abrogates the beneficial effects of GW9662 on weight loss and bacterial burden.

<p>Growth retardation in infected wild type mice is expressed as percent growth from day 0 after challenge (A). Enteroaggregative <i>Escherichia coli</i> (EAEC) burden in the colon was assessed by quantitative real time RT-PCR using bacterial DNA isolated from feces of infected mice treated with 1 µM PPARγ antagonist GW9662 (n = 3), 50 µg anti-IL17 and 1 µM GW9662 combined (n = 3) or untreated (n = 3). Asterisks indicate values where differences are statistically significant (<i>p</i><0.05), NS signifies no significant difference, and bars are present to indicate significance between groups.